To date, multiple mechanisms have been proposed for the resistance to anti-angiogenic therapies, but it mainly occurs thought the secretion of pro-angiogenic factors promoting tumor angiogenesis in a VEGF-independent manner and by the recruitment of myeloid cells, which in turn sustain inflammation. This evidence concerns the gene VEGFA and neoplasm.